Live feed18:00:00·549dPRReleasevia QuantisnowRecursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable TolerabilityByQuantisnow·Wall Street's wire, on your screen.RXRX· Recursion Pharmaceuticals Inc.Health Care
